Global Childhood Vaccination Coverage Stalls After 50 Years of Progress

Routine childhood vaccination is among the most cost-effective public health interventions ever devised, averting an estimated 154 million deaths globally since the Expanded Programme on Immunization launched in 1974. Despite this remarkable half-century legacy, the pace of progress has slowed, and the COVID-19 pandemic exposed deep structural vulnerabilities in immunization delivery worldwide. This analysis, conducted within the Global Burden of Disease Study 2023 framework, provides the most comprehensive update to date of routine childhood vaccine coverage trends and near-future projections.

The researchers modeled 11 vaccine-dose combinations—including DTP1, DTP3, MCV1, MCV2, Pol3, BCG, HepB3, Hib3, PCV3, RotaC, and RCV1—across 204 countries and territories from 1980 to 2023, drawing on 8,042 reviewed data sources yielding 64,546 country-year-vaccine-specific datapoints from household surveys, administrative records, and WHO/UNICEF Joint Reporting Forms. Advanced statistical tools including spatiotemporal Gaussian process regression (ST-GPR) and Bayesian meta-regression (MR-BRT) were used to adjust for administrative data bias, model vaccine scale-up dynamics, and account for COVID-19 pandemic disruptions in a unified framework.

At the global level, coverage for original EPI vaccines nearly doubled between 1980 and 2023. However, this long-term trend masks a troubling recent deceleration: coverage gains slowed between 2010 and 2019 in many countries, and 21 of 36 high-income countries saw declines in at least one core vaccine-dose during this period. The pandemic then drove sharp global coverage declines after 2020 that had not recovered to pre-COVID-19 levels as of 2023. Newer vaccines such as PCV3 and MCV2 continued to expand due to ongoing national introductions, but at slower rates than modeled pre-pandemic trajectories would have predicted.

The zero-dose children metric—children under one year who have not received any DTP doses—tells a similarly sobering story. The count fell 74.9% globally from 1980 to 2019, but rose to a pandemic-era peak of 18.6 million in 2021. By 2023, the figure stood at 15.7 million, with over half residing in just eight countries. Forecasts through 2030 indicate that meeting the Immunization Agenda 2030 goal of halving zero-dose children relative to 2019 will require accelerated, targeted effort, especially in sub-Saharan Africa and South Asia. Of the three life-course vaccine coverage targets assessed (DTP3, PCV3, MCV2), only DTP3 approaches 90% global coverage—and only under an optimistic scenario.

These findings carry urgent implications. Reversing pandemic-era declines, sustaining newly introduced vaccine scale-ups, and closing persistent equity gaps will require strengthened primary health-care infrastructure, countering vaccine misinformation, and precision targeting of high-burden subnational geographies. The WHO's 'Big Catch-Up' initiative and renewed commitments to routine immunization systems are critical. As new vaccines for malaria, dengue, and other diseases enter deployment, the need for resilient, high-coverage immunization platforms has never been more pressing.